With the uncovering of the molecular mechanisms related to neurodegenerative diseases and cancer, the use of classical and novel imidazoline structures has been more frequently noted in recent (2006 - 2012) patented agents for the treatment of neurodegenerative diseases and cancer instead of agents for the treatment of cardiovascular disease noticed earlier.
Bromodomain and extraterminal domain (BET) proteins are
important
regulators of gene transcription and chromatin remodeling. BET family
members BRD4 and BRDT are validated targets for cancer and male contraceptive
drug development, respectively. Due to the high structural similarity
of the acetyl-lysine binding sites, most reported inhibitors lack
intra-BET selectivity. We surmised that protein–protein interactions
induced by bivalent inhibitors may differ between BRD4 and BRDT, conferring
an altered selectivity profile. Starting from nonselective monovalent
inhibitors, we developed cell-active bivalent BET inhibitors with
increased activity and selectivity for BRDT. X-ray crystallographic
and solution studies revealed unique structural states of BRDT and
BRD4 upon interaction with bivalent inhibitors. Varying spacer lengths
and symmetric vs unsymmetric connections resulted in the same dimeric
states, whereas different chemotypes induced different dimers. The
findings indicate that the increased intra-BET selectivity of bivalent
inhibitors is due to the differential plasticity of BET bromodomains
upon inhibitor-induced dimerization.
Several chemical probes have been developed for use in fluorescence polarization screening assays to aid in drug discovery for the bromodomain and extra-terminal domain (BET) proteins. However, few of those have been characterized in the literature. We have designed, synthesized, and thoroughly characterized a novel fluorescence polarization pan-BET chemical probe suitable for high-throughput screening, structure−activity relationships, and hit-to-lead potency and selectivity assays to identify and characterize BET bromodomain inhibitors.
BackgroundDevelopment of small-molecule inhibitors targeting phosphoinositide 3-kinase (PI3K) has been an appealing strategy for the treatment of various types of cancers.Methodology/Principal FindingOur approach was to perform structural modification and optimization based on previously identified morpholinoquinoxaline derivative WR1 and piperidinylquinoxaline derivative WR23 with a total of forty-five novel piperazinylquinoxaline derivatives synthesized. Most target compounds showed low micromolar to nanomolar antiproliferative potency against five human cancer cell lines using MTT method. Selected compounds showed potent PI3Kα inhibitory activity in a competitive fluorescent polarization assay, such as compound 22 (IC50 40 nM) and 41 (IC50: 24 nM), which induced apoptosis in PC3 cells. Molecular docking analysis was performed to explore possible binding modes between target compounds and PI3K.Conclusions/SignificanceThe identified novel piperazinylquinoxaline derivatives that showed potent PI3Kα inhibitory activity and cellular antiproliferative potency may be promising agents for potential applications in cancer treatment.
A series of novel indene-derived retinoic acid receptor α (RARα) agonists have been designed and synthesized. The use of receptor binding, cell proliferation and cell differentiation assays demonstrated that most of these compounds exhibited moderate RARα binding activity and potent antiproliferative activity. In particular, 4-((3-isopropoxy-2,3-dihydro-1H-inden-5-yl)-carbamoyl)benzoic acid (36d), which showed a moderate binding affinity, exhibited a great potential to induce the differentiation of NB4 cells (68.88% at 5 μM). Importantly, our work established indene as a promising skeleton for the development of novel RARα agonists.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.